Shire dodges HAE competition with $5.9B Dyax buyout

Dyax's ($DYAX) Phase III-ready prospect, DX-2930, would have competed directly with Shire's ($SHPG) Cinryze if and when it hit the market. But the Dublin drugmaker found a way to avoid the rivalry: a $5.9 billion buyout of the Massachusetts biotech. The deal will bolster the company's hereditary angioedema (HAE) franchise, which generates 15% of Shire's revenue and about 20% of earnings, Bernstein analyst Ronny Gal said in an investor note. More from FiercePharma

Suggested Articles

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

NICE rejected Spravato over cost concerns and a lack of head-to-head clinical data against other NICE-recommended alternatives.

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?